TNF and psoriasis: Interestingly, targeted (and also systemic) therapy use (TNF-α inhibitors, IL-17 inhibitors, IL-23 inhibitors, and apremilast) was inversely associated with worsening psoriasis, with an estimated odds ratio (OR) of 0.49 [30].